

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial

Grégoire Stalder,^{1,2,3} Madeleine Suffiotti,⁴ Amandine Segot,¹ Alessandra Noto,⁴ Giuseppe Pantaleo,^{3,4} Olivier Spertini^{1,3} and Michel Obeid^{3,4}

¹Service and Central Laboratory of Hematology, Lausanne University Hospital, Lausanne; ²Service of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Sion and ³University of Lausanne, Lausanne and ⁴Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland

Correspondence:

M. OBEID - michel.obeid@chuv.ch

<https://doi.org/10.3324/haematol.2022.281221>

Supplement document

Supplemental Table 1. Patient's and hemophagocytic lymphohistiocytosis diagnosis characteristics	2
Supplemental Figure 1. Differences in the classic parameter between time points of interest at day 0 and day 7 in patients treated with adRED and historical control patients. ...	5
Supplemental Figure 2. Intergroup treatment type data comparisons of low/high doses of etoposide/DEX for patients receiving ruxolitinib were performed via Fisher's exact test. Low-dose etoposide regimen = cumulative dose ≤ 350 mg/m ² . High-dose etoposide = cumulative dose >350 mg/m ² . Low-dose DEX regimen = cumulative dose ≤ 550 mg. High-dose DEX = cumulative dose >550 mg.....	6

Supplemental Table 1. Patient's and hemophagocytic lymphohistiocytosis diagnosis characteristics


	All patients (n=6)	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age (Years)	52 (mean)	61	40	34	72	42	64
Sex	4M /2F	Male	Male	Female	Female	Male	Male
ELN AML risk category							
Intermediate	1 (17%)	0	1	0	0	0	0
Adverse	5 (83%)	1	0	1	1	1	1
Karyotype							
Normal	2 (33%)	0	1	0	0	1	0
Complex	3 (50%)	1	0	0	1	0	1
NGS							
FTL3-ITD	2 (33%)	0	1	0	0	1	0
TP53 mutation	2 (33%)	1	0	0	1	0	0
DNMT3A	1 (17%)	0	1	0	0	0	0
TET2	1 (17%)	0	1	0	0	0	0
ASXL1	1 (17%)	0	0	0	1	0	0
Timing of HLH diagnosis							
At AML diagnosis	2 (33%)	1	0	0	0	0	1
At AML relapse	4 (67%)	0	1	1	1	1	0
After allo-HSCT	2 (33%)	0	1	1	0	0	0

Before intensive chemotherapy	2 (33%)	1	1	0	0	0	0
After intensive chemotherapy	4 (67%)	0	0	1	1	1	1
During C1 chemotherapy	5 (83%)	1	1	1	1	0	1
During C2 chemotherapy	1 (17%)	0	0	0	0	1	0
Type of chemotherapy							
		CLAG-IDA	CLAG	FLAG	7+3	7+3 followed by FLAG	FLAG-IDA
Clinical parameters							
Fever (max. temperature)	6 (100%) (mean 39.3°C)	Yes (39°C)	Yes (39.8°C)	Yes (40°C)	Yes (38.5°C)	Yes (38.9°C)	Yes (39.7°C)
Organomegaly	5/6 (83%)	1	1	1	0	1	1
Laboratory parameters							
Hemophagocytosis on bone marrow biopsy	3 (50%)	0	0	0	1	1	1
Ferritin (µg/L)	37689 (mean)	5962	9250	17394	134490	35728	23309
sCD25 (pg/mL)	7471 (mean)	1196	8182	4612	5551	22010	3273

Triglyceride (mmol/L)	2.2 (mean)	2	1.5	1.9	3.3	3.1	1.5
Fibrinogen (g/L)	5.8 (mean)	5.5	2.4	6.7	1.7	9.4	9.1
ASAT (U/L)	181 (mean)	235	14	42	286	202	309
Hemoglobin (g/L)	85 (mean)	74	71	84	88	107	86
Leukocytes (G/L)	2.2 (mean)	4.6	1.3	<0.1	0.7	<0.1	<0.1
Neutrophils (G/L)	1.57 (mean)	3.45	1.01	<0.1	0.24	<0.1	<0.1
Thrombocytes (G/L)	28 (mean)	67	7	26	28	12	25
HScore	247 (mean)	206	263	214	263	261	272
HLH-2004 criteria	-	5/8	5/8	5/8	5/8	6/8	6/8

Allo-HSCT = allogeneic hematopoietic stem cell transplantation. AML = acute myeloid leukemia.

Supplemental Figure 1. Differences in the classic parameter between time points of interest at day 0 and day 7 in patients treated with adRED and historical control patients.



Supplemental Figure 2. Correlations heatmap between cytokines and classic parameters of patients with acute leukemias and HLH at follow-up. Color scale (blue-to-red) represents Pearson's correlation coefficient.

0.54	0.69	0.07	-0.11	-0.22	0.22	0.24	0.55	-0.08	-0.05	-0.08	-0.49	-0.51	IL-7
0.44	0.26	-0.01	-0.20	-0.16	0.05	0.11	0.33	0.22	0.19	-0.30	-0.80	-0.75	G-CSF
0.77	0.91	0.49	0.32	0.23	0.08	0.38	0.47	0.26	0.35	-0.18	-0.65	-0.68	IL-6
0.76	0.89	0.57	0.41	0.34	0.06	0.39	0.54	0.32	0.28	-0.02	-0.49	-0.58	CXCL8
0.55	0.83	0.40	0.19	0.08	0.21	0.43	0.40	0.19	0.03	-0.37	-0.63	-0.62	CCL2
0.47	0.81	0.44	0.26	0.15	0.34	0.38	0.59	0.18	-0.15	-0.14	-0.34	-0.53	CCL3
0.52	0.76	0.61	0.45	0.43	0.74	0.66	0.67	0.25	0.16	-0.22	-0.06	-0.15	CXCL13
0.29	0.72	0.63	0.68	0.48	0.34	0.81	0.53	0.42	0.18	-0.23	-0.16	-0.32	IL-10
0.43	0.67	0.78	0.62	0.51	0.18	0.58	0.61	0.08	-0.06	-0.02	-0.10	-0.18	CCL4
0.52	0.77	0.66	0.42	0.34	0.22	0.55	0.62	0.25	0.08	-0.14	-0.35	-0.42	CXCL1
0.02	0.33	0.40	0.42	0.29	0.24	0.70	0.55	0.18	-0.12	-0.35	-0.19	-0.19	IFN-gamma
0.10	0.42	0.28	0.31	0.20	0.24	0.72	0.51	-0.08	-0.14	-0.53	-0.16	-0.26	CXCL9
0.23	0.58	0.23	0.27	0.14	0.53	0.79	0.45	-0.08	0.08	-0.50	-0.13	-0.22	IL-18
0.38	0.46	0.26	0.16	0.17	0.42	0.69	0.64	0.12	0.15	-0.51	-0.35	-0.43	sCD25
-0.18	0.25	0.16	-0.11	0.03	0.21	-0.21	-0.44	-0.17	-0.27	0.17	0.28	0.42	CCL11
-0.08	0.13	0.16	0.42	0.23	0.04	0.06	-0.03	0.08	-0.05	0.46	0.04	-0.02	BDNF
-0.18	-0.04	0.19	0.46	0.33	-0.07	-0.10	-0.10	0.07	-0.05	0.66	0.35	0.29	EGF
0.10	0.24	0.64	0.61	0.67	0.21	0.51	0.16	-0.08	0.23	0.32	0.01	-0.04	IL-1RA
0.20	0.56	0.46	0.40	0.34	0.43	0.34	0.28	-0.18	-0.42	-0.13	0.23	0.16	CCL5
0.22	0.64	0.47	0.52	0.35	0.39	0.65	0.38	-0.18	-0.16	-0.26	0.17	0.07	CXCL10
0.61	0.74	0.56	0.54	0.48	0.35	0.33	0.45	0.43	0.14	0.25	0.09	0.05	HGF
0.62	0.77	0.42	0.28	0.19	0.27	0.16	0.50	0.04	-0.30	-0.00	0.02	0.04	SCF
0.28	0.18	0.49	0.31	0.55	0.37	0.11	0.20	-0.22	-0.20	0.04	0.39	0.37	PDGF-BB
0.27	0.57	0.36	0.42	0.21	-0.08	0.09	0.03	-0.06	-0.23	0.37	0.23	0.25	VEGF-A
0.35	0.57	0.56	0.59	0.45	-0.05	0.18	0.37	0.04	-0.27	0.28	0.08	0.03	CXCL12
0.18	0.33	0.46	0.47	0.47	-0.14	-0.10	0.27	0.11	-0.29	0.48	0.23	0.23	PIGF-1
Fibrogene	CRP	LDH	ASAT	ALAT	Triglycerides	Ferritin	Bilirubin	Hemoglobin	D_dimers	Thrombocytes	Leucocytes	Neutrophiles	